[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE404545T1 - Acylaminothiazolderivate, verfahren zu deren herstellung und deren verwendung als inhibitoren der produktion von beta-amyloidpeptid - Google Patents

Acylaminothiazolderivate, verfahren zu deren herstellung und deren verwendung als inhibitoren der produktion von beta-amyloidpeptid

Info

Publication number
ATE404545T1
ATE404545T1 AT04704255T AT04704255T ATE404545T1 AT E404545 T1 ATE404545 T1 AT E404545T1 AT 04704255 T AT04704255 T AT 04704255T AT 04704255 T AT04704255 T AT 04704255T AT E404545 T1 ATE404545 T1 AT E404545T1
Authority
AT
Austria
Prior art keywords
production
inhibitors
beta
amyloid peptide
acylaminothiazole derivatives
Prior art date
Application number
AT04704255T
Other languages
English (en)
Inventor
Pierre Despeyroux
Daniel Frehel
Bruno Schoentjes
Dorsselaer Viviane Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE404545T1 publication Critical patent/ATE404545T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04704255T 2003-01-23 2004-01-22 Acylaminothiazolderivate, verfahren zu deren herstellung und deren verwendung als inhibitoren der produktion von beta-amyloidpeptid ATE404545T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0300703A FR2850380B1 (fr) 2003-01-23 2003-01-23 Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique

Publications (1)

Publication Number Publication Date
ATE404545T1 true ATE404545T1 (de) 2008-08-15

Family

ID=32669150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04704255T ATE404545T1 (de) 2003-01-23 2004-01-22 Acylaminothiazolderivate, verfahren zu deren herstellung und deren verwendung als inhibitoren der produktion von beta-amyloidpeptid

Country Status (24)

Country Link
US (2) US7563903B2 (de)
EP (1) EP1590337B1 (de)
JP (1) JP2006515888A (de)
KR (1) KR101059669B1 (de)
CN (1) CN100532370C (de)
AR (1) AR042745A1 (de)
AT (1) ATE404545T1 (de)
AU (1) AU2004207658B2 (de)
BR (1) BRPI0406893A (de)
CA (1) CA2511610A1 (de)
DE (1) DE602004015726D1 (de)
FR (1) FR2850380B1 (de)
HR (1) HRP20050637A2 (de)
IL (1) IL169428A (de)
MA (1) MA27610A1 (de)
ME (1) MEP16708A (de)
MX (1) MXPA05007847A (de)
NO (1) NO330415B1 (de)
NZ (1) NZ541147A (de)
PL (1) PL377999A1 (de)
RS (1) RS51168B (de)
RU (1) RU2360907C2 (de)
TW (1) TWI320710B (de)
WO (1) WO2004067520A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4220548B2 (ja) * 2003-06-05 2009-02-04 エラン ファーマシューティカルズ，インコーポレイテッド アシル化されたアミノ酸・アミジルピラゾール、および関連化合物
BRPI0706621A2 (pt) * 2006-01-18 2011-04-05 Amgen Inc composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
WO2009108760A2 (en) 2008-02-26 2009-09-03 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
EP2371421A1 (de) * 2010-03-04 2011-10-05 Université de Lille 2 Droit et Santé Liganden von insulinabbauenden Enzymen und ihre Verwendungen
EP2508511A1 (de) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitoren der Virenreplikation, Verfahren zu deren Herstellung und deren therapeutische Verwendung
CN103145692B (zh) * 2013-03-12 2014-07-16 盐城工学院 一种4,5-二氢-6H-环戊烷并[b]噻吩-6-酮的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335280A (en) * 1996-11-22 2001-05-25 Lilly Co Eli D-penicillamine derivatives for treating beta-amyloid type diseases such as Alzheimer's disease
TR199901343T2 (xx) * 1996-12-23 1999-09-21 Elan Pharmaceuticals, Inc. Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
ATE288904T1 (de) * 1998-06-18 2005-02-15 Bristol Myers Squibb Co Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
WO2000024392A1 (fr) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited Inhibiteur de la formation de beta-amyloide
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios

Also Published As

Publication number Publication date
RU2360907C2 (ru) 2009-07-10
RS20050563A (en) 2007-06-04
JP2006515888A (ja) 2006-06-08
DE602004015726D1 (de) 2008-09-25
FR2850380B1 (fr) 2006-07-07
RS51168B (sr) 2010-10-31
AR042745A1 (es) 2005-06-29
BRPI0406893A (pt) 2006-01-03
KR20050094039A (ko) 2005-09-26
US7563903B2 (en) 2009-07-21
US20060052426A1 (en) 2006-03-09
EP1590337A1 (de) 2005-11-02
NO330415B1 (no) 2011-04-11
MEP16708A (en) 2010-06-10
MA27610A1 (fr) 2005-11-01
AU2004207658B2 (en) 2009-10-29
CA2511610A1 (en) 2004-08-12
CN1777593A (zh) 2006-05-24
NZ541147A (en) 2008-06-30
CN100532370C (zh) 2009-08-26
MXPA05007847A (es) 2006-05-17
FR2850380A1 (fr) 2004-07-30
AU2004207658A1 (en) 2004-08-12
TW200503699A (en) 2005-02-01
US20090253753A1 (en) 2009-10-08
EP1590337B1 (de) 2008-08-13
PL377999A1 (pl) 2006-02-20
IL169428A (en) 2010-12-30
NO20053588L (no) 2005-09-22
NO20053588D0 (no) 2005-07-22
KR101059669B1 (ko) 2011-08-25
HRP20050637A2 (en) 2005-10-31
US7879889B2 (en) 2011-02-01
WO2004067520A1 (fr) 2004-08-12
RU2005126608A (ru) 2006-04-27
TWI320710B (en) 2010-02-21

Similar Documents

Publication Publication Date Title
ATE476412T1 (de) Acyl-4-carboxy-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
ATE381552T1 (de) Derivate von 1-piperazin- und 1- homopiperazincarboxylaten, verfahren zu deren herstellung und deren verwendung als inhibitoren des faah-enzyms
DE602004015570D1 (de) Makromolekulare ketoaldehyden und verfahren zu dessen herstellung
DE502005010912D1 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE60333438D1 (de) Beschichtete gefässprothesen, verfahren zu deren herstellung und verwendung derselben
ATE556077T1 (de) Tetrahydrochinolinderivate und verfahren zu deren herstellung
DE60324376D1 (de) Halbleiterbauelement und Verfahren zu dessen Herstellung
ATE452879T1 (de) Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE331705T1 (de) Alpha-aminosäure-derivate, verfahren zu deren herstellung sowie deren verwendung als dipeptidylpeptidase-iv inhibitoren (dpp iv)
ATE535518T1 (de) Derivate von piperidinyl- und piperazinylalkylcarbamaten, verfahren zu deren herstellung und deren verwendung in therapeutika
ATE482207T1 (de) Cyclische harnstoffderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung als kinaseinhibitoren
ATE346065T1 (de) Substituierte thiazol- benzoisothiazoldioxidderivative, verfahren zu deren herstellung und deren verwendung
DE50310782D1 (de) Piezoaktor und verfahren zu dessen herstellung
ATE482193T1 (de) Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen
ATE380184T1 (de) Derivate von alkylpiperazin- und alkylhomopiperazincarboxylaten, verfahren zu deren herstellung und deren verwendung als inhibitoren des faah-enzyms
DE60313818D1 (de) Dialysator und Verfahren zu dessen Herstellung
ATE327981T1 (de) Arylisoxazolin-derivative, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
DE60335812D1 (de) Biosensor und verfahren zu seiner herstellung
DE60329744D1 (de) Aminosäurepulver und verfahren zu seiner herstellung
ATE496046T1 (de) Arylvinylazacycloalkan-verbindungen und verfahren zu deren herstellung und verwendung
DE112004002104A5 (de) Hochtackige Klebmasse, Verfahren zu deren Herstellung und deren Verwendung
DE60307830D1 (de) Neue multimerische moleküle, verfahren zu deren herstellung, und deren verwendung zur herstellung von arzneimitteln
ATE478045T1 (de) Derivate von 4,5-diarylpyrrol, verfahren zu deren herstellung und deren verwendung in therapeutika
ATE404545T1 (de) Acylaminothiazolderivate, verfahren zu deren herstellung und deren verwendung als inhibitoren der produktion von beta-amyloidpeptid
DE602004031350D1 (de) Penamkristall und verfahren zu dessen herstellung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties